LETTER TO THE EDITOR
In vitro studies of dasatinib, its targets and predictors of sensitivity
Version of Record online: 10 MAR 2011
© 2011 John Wiley & Sons A/S
Pigment Cell & Melanoma Research
Volume 24, Issue 2, pages 386–389, April 2011
How to Cite
Jilaveanu, L. B., Zito, C. R., Aziz, S. A., Chakraborty, A., Davies, M. A., Camp, R. L., Rimm, D. L., Dudek, A., Sznol, M. and Kluger, H. M. (2011), In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell & Melanoma Research, 24: 386–389. doi: 10.1111/j.1755-148X.2011.00835.x
- Issue online: 10 MAR 2011
- Version of Record online: 10 MAR 2011
- Accepted manuscript online: 15 FEB 2011 04:01AM EST
Data S1. Materials and methods.
Figure S1. Membranous and cytoplasmic expression of Src proteins in melanoma histospots.
Figure S2. Effect of dasatinib inhibition on protein expression.
Figure S3. Caveolin-1 expression in pre-treatment tumors of melanoma patients treated with dasatinib who either had a partial response or tumor reduction.
Table S1. Automated, quantitative analysis score distribution and numbers of assessable cases for each marker in TMAs.
Table S2. IC50 of dasatinib in a panel of melanoma cell lines.
Table S3. List of Antibodies for Reverse Phase Protein Arrays.
|PCMR_835_sm_Tables-figs-methods.doc||6503K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.